Recce Pharmaceuticals Ltd (ASX:RCE)

Market Cap	107.81M -11.2%
Revenue (ttm)	9.94M -89.8%
Net Income	-14.96M
EPS	-0.05
Shares Out	299.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,870
Open	0.3700
Previous Close	0.3600
Day's Range	0.3600 - 0.3700
52-Week Range	0.3470 - 0.7300
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RCE

Financial Performance

In fiscal year 2026, Recce Pharmaceuticals's revenue was 9.94 million, an increase of 32.36% compared to the previous year's 7.51 million. Losses were -14.96 million, -30.18% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error